Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Rheumatoid Arthritis

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Arthritis Care Res (Hoboken)

Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA

doi: 10.1002/acr.25437

Rheumatoid Arthritis

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Lancet Rheumatol

Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB

doi: 10.1016/S2665-9913(24)00221-2

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Arthritis Rheumatol

Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, Forsblad-d'Elia H, Kastbom A, Olofsson T, Frisell T, Turesson C

doi: 10.1002/art.43014

Psoriatic Arthritis

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set

Ann Rheum Dis

Charlton RA, Gates E, Coates LC, Galloway J, McHugh N, McGrogan A, Hackett S, Brooke M, Cavill C, Tillett W

doi: 10.1016/j.ard.2025.02.020

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Further Publications Rheumatology

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

Ann Rheum Dis

Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Buch MH, Burmester GR, Canhão HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimarães V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Sedmak N, Silva-Fernández L, Szekanecz Z, Lauper K, Finckh A, Gottenberg JE

doi: 10.1136/ard-2024-225981

Related content

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer